HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unilever’s Growth Action Plan Rooted In ‘Fewer Things Better’

Executive Summary

CEO Hein Schumacher provided awaited detail on Unilever’s new Growth Action Plan, which seeks to leverage R&D strengths and winning technology platforms while driving productivity improvements, in an 8 February year-end sales presentation. The firm reported underlying net sales growth of 7% in fiscal 2023 to 59.6bn.

You may also be interested in...

PCPC’s New Legal Head, Unilever’s K18 Acquisition, Lauder’s Skin Longevity Platform; Beauty Industry News

The Personal Care Products Council names Emily Manoso executive VP, legal and regulatory affairs and general counsel, replacing Tom Myers who has taken the group’s helm as president and CEO. Unilever acquires San Francisco-based hair care brand K18 for an undisclosed price. More beauty industry news.

Unilever Divests Dollar Shave Club, Focused On 30 ‘Power Brands’ Under New CEO’s Action Plan

More brands, particularly those acquired prior to Unilever’s 2019 shift in M&A strategy, could be on the chopping block, according to CEO Hein Schumacher, who took the helm in July. His targeted action plan includes investments to accelerate innovation and increase brand and marketing support.

HBW Market Executive Decisions: Unilever’s Next CEO, CRN Staff, GOED Board, PLZ CEO

Unilever names Schumacher as Jope’s successor at CEO; specialty aerosol, liquid products firm PLZ appoints CEO; GOED seats 2023 board officers; and CRN adds and promotes staff members.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts